Sublingual Misoprostol in Reduction of Caesarean Blood Loss

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

152 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-14

Study Completion Date

2023-11-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Caesarean delivery is inevitably associated with a higher amount of blood loss vis-à-vis primary postpartum haemorrhage, when compared to vaginal delivery. Oxytocin use in tropical developing countries for the reduction blood loss at caesarean section have been met with challenges of ineffectiveness due to poor transportation, inadequate storage and drug adulteration. Therefore, there is a need for an effective, temperature stable uterotonic with a lesser risk of adulteration. The study is aimed at evaluating the effectiveness and safety of adjunctive sublingual misoprostol in reducing intraoperative blood loss at caesarean section.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sublingual vs Intrauterine MISOPROSTOL Plus Oxytocin Infusion for Prevention of Post-cesarean Hemorrhage in High Risk Pregnant Women: A Double-blind Placebo RCT

NCT04560218

To Compare Efficacy Intrauterine vs Sublingual MISOPROSTOL in Addition to Oxytocin in Reducing Blood Loss of Post-cesarean Section in High Risk Women

COMPLETED PHASE3

Misoprostol in the Prevention of Postpartum Haemorrhage

NCT04044287

Postpartum Hemorrhage

UNKNOWN PHASE3

Comparative Study on the Effects of Sublingual Misoprostol in Addition to Standard AMTSL in Low Risk Parturients in LASUTH, Ikeja.

NCT02424201

Primary Postpartum Haemorrhage

UNKNOWN EARLY_PHASE1

Sublingual Misoprostol & Isoflurane During Caesarean Section

NCT01466530

Pregnancy Cesarean Delivery

COMPLETED PHASE2

Could Pre-operative Rectal Misoprostol Reduce Intra-operative Blood Loss During Ceserean Section?

NCT02509351

Postpartum Haemorrhage

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It would be a double blind randomized controlled trial. One hundred and fifty-two pregnant women at term who have indications for caesarean section and have risk factors for primary postpartum haemorrhage, as well as meet the eligibility criteria would be randomized equally into two study arms (Misoprostol study arm and Placebo study arm) after informed consent. The Misoprostol study arm will receive 400 mcg of sublingual misoprostol as two 200 mcg misoprostol tablets. The Placebo study arm would receive two sublingual placebo tablets similar to the misoprostol tablets. The Misoprostol and the Placebo tablets will be given in each study arm at the point of starting the uterine incision at caesarean section. Both study arms would receive routine intravenous oxytocin at the time of clamping of the umbilical cord. The outcome measures will be estimated intraoperative blood loss, the need for additional intraoperative oxytocic, blood transfusion, the occurrence of side effects, and incidence of primary postpartum haemorrhage.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post Partum Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

A hospital's pharmacist/pharmacologist will manufacture the misoprostol tablets at doses of 200 mcg each as well as the placebo tablets (which will contain vitamin B complex excipient only). The misoprostol tablets and placebo tablets will be indistinguishable. Envelopes will be pre-packed, sealed and outwardly labelled by a hospital's pharmacist/pharmacologist who will take no further part in the study.

Each pre-packed envelope will contain three 200 mcg misoprostol tablets for the misoprostol arm or three placebo tablets (which will contain vitamin B complex excipient only) for the placebo arm.

The randomization list will be in the possession of a research assistant who will take no further part in the study after randomly allocating the participants to the study arms, till the end of the study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Misoprostol

400 mcg of sublingual misoprostol as two 200 mcg misoprostol tablets at the point of starting the uterine incision at caesarean section, then bolus administration of 10 IU of intravenous oxytocin followed by an infusion of 20 IU of oxytocin in 500 ml of normal saline at a rate of twenty drops per minute to run over eight hours.

Group Type EXPERIMENTAL

Misoprostol

Intervention Type DRUG

The misoprostol tablets to be used in the study will be of the same brand and batch

Oxytocin

Intervention Type DRUG

The oxytocin ampoules to be used in the study will be of the same brand and batch

Placebo

Two sublingual placebo tablets similar to the misoprostol tablets at the point of starting the uterine incision at caesarean section, then bolus administration of 10 IU of intravenous oxytocin followed by an infusion of 20 IU of oxytocin in 500 ml of normal saline at a rate of twenty drops per minute to run over eight hours.

Group Type PLACEBO_COMPARATOR

Oxytocin

Intervention Type DRUG

The oxytocin ampoules to be used in the study will be of the same brand and batch

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Misoprostol

The misoprostol tablets to be used in the study will be of the same brand and batch

Intervention Type DRUG

Oxytocin

The oxytocin ampoules to be used in the study will be of the same brand and batch

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnant women at term (37+0 weeks to 41+6 weeks gestational age) for elective or non-elective caesarean sections
* Pregnant women who have risk factor for primary postpartum haemorrhage
* Pregnant women who consent to participate in the study

Exclusion Criteria

* Pregnant women who withhold consent to participate in the study
* Caesarean sections for dire emergencies (umbilical cord prolapse, suspected fetal distress and active antepartum haemorrhage)
* Previous caesarean sections or other uterine surgeries
* Pregnant women with no risk factor for primary postpartum haemorrhage
* Allergy to misoprostol use
* Known history of hepatic, renal and haematological disorders
* Caesarean section to be done under general anaesthesia
* Fever (temperature ≥ 37.5 degrees centigrade)
* Pre-operative anaemia (pre-operative haematocrit level \< 30 %)
* Pregnant women who are unconscious or have eclampsia

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No